Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 sentry antimicrobial surveillance program

Diagnostic Microbiology and Infectious Disease

Volumn 71, Issue 4, 2011, Pages 415-420

  Farrell, David J ^a   Liverman, Lisa C ^b   Biedenbach, Douglas J ^a   Flamm, Robert K ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

^b Furiex Pharmaceuticals   (United States)

Author keywords

Fluoroquinolone; JNJ Q2; MRSA; Staphylococcus aureus

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; JNJ Q2; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OXACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; BROTH DILUTION; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; GEOGRAPHIC ORIGIN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SKIN INFECTION; SPECIES DIFFERENCE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; ASIA; EUROPE; FLUOROQUINOLONES; HUMANS; LATIN AMERICA; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PYOGENES;

EID: 82555179101     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.08.011     Document Type: Article

References (16)

1. Blumberg H.M., Rimland D., Carroll D.J., Terry P., Wachsmuth I.K. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J. Infect. Dis. 1991, 163:1279-1285.
2. Bolon M.K. The newer fluoroquinolones. Infect. Dis. Clin. North. Am. 2009, 23:1027-1051.
3. Clinical and Laboratory Standards Institute M07-A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 2009, Clinical and Laboratory Standards Institute, Wayne, PA. 8th ed.
4. Clinical and Laboratory Standards Institute M100-S21. Performance standards for antimicrobial susceptibility testing; 21st informational supplement 2011, Clinical and Laboratory Standards Institute, Wayne, PA.
5. Corey G.R., Wilcox M.H., Talbot G.H., Thye D., Friedland D., Baculik T. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 2010, 65:iv41-iv51.
6. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin. Infect. Dis. 2006, 42(Suppl 1):S25-S34.
7. EUCAST Clinical MIC breakpoints http://www.eucast.org/clinical_breakpoints/.
8. Farrell D.J., Liverman L.C., Biedenbach D.J., Jones R.N. JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains. Antimicrob. Agents Chemother. 2011, 55:3631-3634.
9. Farrell D.J., Mendes R.E., Ross J.E., Sader H.S., Jones R.N. LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States. Antimicrob. Agents Chemother. 2011, 55:3684-3690.
10. Krause K.M., Barriere S.L., Kitt M.M., Benton B.M. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies. Diagn. Microbiol. Infect. Dis. 2010, 68:181-185.
11. McCaig L.F., McDonald L.C., Mandal S., Jernigan D.B. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg. Infect. Dis. 2006, 12:1715-1723.
12. Morrow B.J., He W., Amsler K.M., Foleno B.D., Macielag M.J., Lynch A.S., Bush K. In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone. Antimicrob. Agents. Chemother. 2010, 54:1955-1964.
13. National Nosocomial Infections Surveillance National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control. 2004, 32:470-485.
14. Ross J.E., Farrell D.J., Mendes R.E., Sader H.S., Jones R.N. Eight-year (2002-2009) summary of the linezolid (Zyvox(R) Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries. J. Chemother. (Florence, Italy) 2011, 23:71-76.
15. Spellberg B., Guidos R., Gilbert D., Bradley J., Boucher H.W., Scheld W.M., Bartlett J.G., Edwards J. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 2008, 46:155-164.
16. Wilcox M.H., Corey G.R., Talbot G.H., Thye D., Friedland D., Baculik T. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 2010, 65:iv53-iv65.